問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Digestive System Department

Division of Thoracic Medicine

更新時間：2023-09-19

蔡佳叡Tsai, Jia-Ruey
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

21Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡佳叡

List

27Cases

2024-04-01 - 2028-01-31

Phase I

Active
A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting8Sites

Terminated1Sites

2021-03-16 - 2029-12-31

Phase III

Active
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

  • Condition/Disease

    AZD9833 AZD9833 is being developed for treatment of ER-positive, HER2-negative breast cancer. Anastrozole Arimidex is indicated for the: -Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. -Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women. -Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen. Palbociclib IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: -in combination with an aromatase inhibitor; -in combination with fulvestrant in women who have received prior endocrine therapy (see section 5.1). In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

  • Test Drug

    AZD9833 ArimidexR IbranceR

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

2021-06-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting9Sites

Recruiting2Sites

2021-01-01 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2024-06-01 - 2027-12-31

Phase I

Active
A Phase 1, First-in-Human, Open-label, Dose- escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 in Subjects with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

2023-07-07 - 2026-07-31

Phase I

Active
A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug (ABBV-514) as a Single Agent and in Combination with Budigalimab or Bevacizumab

  • Condition/Disease

    NSCLC, HNSCC, and Advanced Solid Tumors

  • Test Drug

    N/A N/A

Participate Sites
5Sites

Recruiting5Sites

2022-04-01 - 2028-09-30

Phase III

Active
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLS

  • Test Drug

    Telisotuzumab Vedotin (ABBV-399)

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2022-09-01 - 2025-12-31

Phase I

Active
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ABBV-400

Participate Sites
11Sites

Not yet recruiting3Sites

Recruiting8Sites

2025-04-01 - 2027-12-31

Phase III

Active
A multicenter, open-label, randomized phase 3 trial evaluating sequential treatment with THIO followed by cemiplimab (LIBTAYO®) versus investigator’s choice of single-agent chemotherapy as third-line therapy in participants with advanced or metastatic non–small cell lung cancer (NSCLC).

  • Condition/Disease

    Advanced non–small cell lung cancer (NSCLC)

  • Test Drug

    LIBTAYO THIO

Participate Sites
10Sites

Recruiting10Sites

2021-10-01 - 2027-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting13Sites

Terminated3Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB